CAPTRUST Financial Advisors
TELO icon

CAPTRUST Financial Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$61.4K Hold
51,194
– – ﹤0.01% 3226
2026
Q2 		$65.5K Buy
+51,194
New +$66.7K ﹤0.01% 3098

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $582M AUM 12.38% 1-Year Est. Return
OneDigital Investment Advisors
OneDigital Investment Advisors Overland Park, Kansas $12.7B AUM 13.94% 1-Year Est. Return
Morton Capital Management
Morton Capital Management Calabasas, California $828M AUM 13.29% 1-Year Est. Return

CAPTRUST Financial Advisors's TELO Position: Q3 2026 in Review

CAPTRUST Financial Advisors held its Telomir Pharmaceuticals (TELO) position steady in Q3 2026 at 51,194 shares worth $61.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3226.

CAPTRUST Financial Advisors first reported a position in TELO in Q2 2026 and has held it in 2 quarters since. The position peaked at $65.5K in Q2 2026. 22 funds tracked by Wall St. Rank hold TELO as of Q3 2026.

  • CAPTRUST Financial Advisors held 51,194 shares of Telomir Pharmaceuticals worth $61.4K as of Q3 2026.
  • CAPTRUST Financial Advisors left its Telomir Pharmaceuticals share count unchanged in Q3 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3226 holding.
  • CAPTRUST Financial Advisors first reported a position in Telomir Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • CAPTRUST Financial Advisors's Telomir Pharmaceuticals position peaked at $65.5K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.